Who
Paul Anthony Williams
SVP, Products Business
Company insider
Files Form 4 as: SVP, Products Business, Emergent BioSolutions.
In numbers
- Trades disclosed
- 40
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $138K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 23 Feb 2023
- Last trade
- 1 Oct 2026
- Last filed
- 5 Oct 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 5 Oct 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $20K3,000 at $6.53 | filing |
| 1 Jul 2026filed 2 Jul 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $25K3,000 at $8.40 | filing |
| 1 Jul 2026filed 2 Jul 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $25K3,000 at $8.40 | filing |
| 8 Jun 2026filed 10 Jun 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $5,552694 at $8.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $5,552694 at $8.00 | filing |
| 29 Apr 2026filed 1 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —100,111 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —100,111 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $34K4,000 at $8.44 | filing |
| 1 Apr 2026filed 3 Apr 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Sold | $34K4,000 at $8.44 | filing |
| 5 Mar 2026filed 5 Mar 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $79K9,397 at $8.44 | filing |
| 5 Mar 2026filed 5 Mar 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $79K9,397 at $8.44 | filing |
| 3 Mar 2026filed 5 Mar 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,834 at $0.00 | filing |
| 3 Mar 2026filed 5 Mar 2026 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —44,834 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $945116 at $8.15 | filing |
| 1 Mar 2026filed 3 Mar 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $945116 at $8.15 | filing |
| 6 Feb 2026filed 10 Feb 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code D | $95K8,655 at $10.92 | filing |
| 6 Feb 2026filed 10 Feb 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $11K1,022 at $10.92 | filing |
| 6 Feb 2026filed 10 Feb 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code D | $95K8,655 at $10.92 | filing |
| 6 Feb 2026filed 10 Feb 2026 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $11K1,022 at $10.92 | filing |
| 8 Jun 2025filed 10 Jun 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code F | $3,076464 at $6.63 | filing |
News
Comparing Monte Rosa Therapeutics (NASDAQ:GLUE) and Emergent Biosolutions (NYSE:EBS)EBS · tickerreport.com · 16 Oct 2026Critical Survey: Emergent Biosolutions (NYSE:EBS) & Viridian Therapeutics (NASDAQ:VRDN)EBS · dailypolitical.com · 6 Oct 2026
0 headlines in the last 90 days name Paul Anthony Williams; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.